Kaiser Permanente announces completion of HealthConnect effort
OAKLAND, Calif. Kaiser Permanente announced recently that all of its 8.7 million members in nine states and the District of Columbia are now covered by an outpatient electronic health record, called HealthConnect.
Also, all of Kaiser Permanente’s 13,000 physicians now have electronic access to their patients’ medical records in every one of their 421 medical offices/clinics.
HealthConnect has improved patient safety, coordination of care, as well as enhancing documentation, facilitating clinical decision making and adherence to evidence-based clinical guidelines, and provider and operational efficiency. After the implementation of HealthConnect in the outpatient setting, Kaiser Permanente reported an immediate and marked increase in the efficiency of outpatient care, in large part due to now-24/7 availability of members’ clinical information at every member contact.
Members began using secure messaging and increased utilization of telephone visits—in lieu of in-person visits. Physicians reported that, in many cases, EHRs enabled them to identify and resolve patients’ health issues in the first contact. One survey showed that, with the use of EHRs, medication administration times and doses were more legible and correct (85 percent), and clinicians believed the electronic medication administration system provided a safer and more reliable communication tool (75 percent).
“The implementation of a system this complex, this broadly and deeply in an organization of our size is unprecedented, so I am extremely proud of this accomplishment,” said Jack Cochran, executive director of The Permanente Federation.
Wal-Mart’s $4 generic program expanded again
BENTONVILLE, Ark. Wal-Mart’s $4 generic drug program was expanded on Monday to include new elements such as a 90-day, $10 option, several new women’s medicines and 1,000 nonprescription medicines priced at $4 or less.
This is the third time the program has been expanded since it was introduced in the fall of 2006. Since then, Wal-Mart contends, it has saved customers more than $1.1 billion and up to 95 percent of the prescriptions written in the majority of therapeutic categories now are included in the $4 prescription program. In addition, customers now can purchase a 90-day supply of 350 medicines for $10, a change Wal-Mart said gives customers an additional choice and saves them time and money.
Other changes include the addition of medicines such as a generic version of the osteoporosis drug Fosamax for $9 for a 30-day supply or $24 for a 90-day supply. In addition, medications to treat breast cancer (tamoxifen), menopause and hormone deficiency were added to the list of $9 medicines, a pricing tier that was added to the program in September 2007.
The other notable change to the program involved the inclusion of branded and private-label nonprescription drugs. More than 1,000 products, roughly one-third of the OTC drugs available at Wal-Mart and Neighborhood Market stores are available for $4.
“We’re succeeding in our efforts to deliver simple, affordable, quality pharmacy solutions for families struggling with the rising costs of health care,” said John Agwunobi, president of Wal-Mart’s health and wellness division.
Wal-Mart has promoted the $4 program extensively since its introduction via television commercials, print ads and signage throughout its stores to encourage customers to visit the pharmacy. In addition, the $4 program is frequently held up by Wal-Mart senior executives as an example of the retailer’s marketing slogan adopted last summer to help customers save money so they can live better.
IDSA agrees to re-examine chronic Lyme disease guidelines
HARTFORD, Conn. The Infectious Diseases Society of America has agreed to review its guidelines, which say there’s no evidence long-term antibiotics can cure “chronic” Lyme disease—or even that such a condition exists, according to the Washington Post.
The agreement, announced Thursday, calls for the doctors group to form a new panel of experts to review standards for treating Lyme disease. The IDSA says it agreed to the deal in part because the panel must be made up of doctors and scientists.
Lyme disease can be hard to diagnose with its vague, flu-like symptoms; the most obvious sign is its trademark round red rash. Usually, it’s easily cured with a few weeks of antibiotics. Those not promptly treated can develop arthritis, meningitis and other serious illnesses.
The IDSA says it’s never been proven whether these patients still have Lyme disease or something else. The group continues to defend its standards, which say short-term antibiotics are effective for nearly all patients. Long-term antibiotics are unproven and potentially dangerous, because overuse of the drugs can lead to drug-resistant infections, the society says.
“We are confident that our guidelines for the diagnosis and treatment of Lyme disease represent the best advice that medicine currently has to offer … and we look forward to the opportunity to put to rest any questions about them,” said Donald Poretz, the society’s president.
The society will consider a variety of scientific evidence and determine whether the 2006 guidelines are justified or need revision.
The guidelines are important because they discourage adequate treatment, advocates of chronic Lyme sufferers say. Perhaps just as significant is that insurance companies refuse to pay for long-term antibiotics to treat chronic Lyme disease because they follow the panel’s guidelines.
The doctors group makes clear that current guidance for treating Lyme disease remains in place.